Latest Fentanyl Stories
REDWOOD CITY, Calif., Nov. 15, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line data showing that the open-label Phase 3 study of its investigational sublingual (under the tongue) Sufentanil NanoTab PCA (patient-controlled analgesia) System met its primary endpoint of...
REDWOOD CITY, Calif., Nov. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today it had met the primary endpoint in the Phase 3 non-inferiority study of the sublingual Sufentanil NanoTab PCA System vs. IV PCA with morphine. The top-line data is expected to be released prior to market opening on...
RALEIGH, N.C., Nov. 8, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of the Company's recent achievements and upcoming milestones. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) "This has been a year of remarkable progress,...
REDWOOD CITY, Calif., Nov. 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2012 and provided a corporate update. Net loss for the third quarter of 2012 was $8.6 million, or $0.38 per share, compared with a net loss of $5.8...
CUPERTINO, Calif., Nov. 5, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2012. Total revenues were $3.8 million for the three months ended September 30, 2012 as compared to $8.1 million for the three months ended September 30, 2011. Net loss for the three months ended September 30, 2012 was $4.8 million, compared to a net loss of $5.0 million for the same period in 2011. (Logo:...
REDWOOD CITY, Calif., Nov. 5, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate. This study will enroll approximately 100 patients following...
CUPERTINO, Calif., Oct. 30, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 5, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...
MIAMI LAKES, Fla., Oct. 23, 2012 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com), an innovative company that possesses proprietary delivery technology set to redefine how consumers receive energy, medicines, vitamins and minerals, today provides further insight into the numerous potential applications of their technology arising from their most recent scientific testing research results. The conclusions of the research documented that the Company can deliver a...
RALEIGH, N.C., Oct. 18, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today reaffirmed its continued strong position and ongoing progress made in its defense of a process patent infringement lawsuit previously served against BDSI and its partners for ONSOLIS, by MonoSolRx, LLC (MonoSol). BDSI reaffirms that its products and technologies do not infringe on MonoSol's original patents, and BDSI believes that its position in this matter has only been...
WOODCLIFF LAKE, N.J., Oct. 15, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into agreements with Watson Pharmaceuticals, Inc. (NYSE: WPI) and Actavis Group to purchase for cash five generic products that are currently marketed in the U.S. by Watson or Actavis, eight Abbreviated New Drug Applications currently awaiting regulatory approval and a generic product in late-stage development. The closing of the purchase agreements is...
